ARB 001
Alternative Names: ARB-001Latest Information Update: 02 Aug 2023
At a glance
- Originator Arbele
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Colorectal cancer
Most Recent Events
- 06 Jul 2023 Arbele has patent pending for ARB 001 in Europe, China and South Korea, prior to July 2023
- 06 Jul 2023 Arbele has patent protection for ARB 001 in Australia, Israel, China, Japan, USA, prior to July 2023
- 06 Jul 2023 Preclinical trials in Colorectal cancer (Metastatic disease) in Hong Kong (Parenteral), prior to July 2023 (Arbele pipeline, July 2023)